About Us
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for developing medicines in the field of oncology – one that revolves around collaboration, shared learning, and excellence.
Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.
We have a seasoned and effective executive team steeped in science, with proven expertise across a broad range of disciplines and an unwavering commitment to delivering on our mission for patients.
Michael A. Metzger
Chief Executive Officer and Director
Keith A. Goldan
Chief Financial Officer
Anjali Ganguli, Ph.D.
Chief Business Officer
Kate Madigan, M.D.
Chief Medical Officer
Kevin McManus
Chief People Officer
Luke J. Albrecht
General Counsel
Neil Gallagher, M.D., Ph.D.
President, Head of Research and Development
Peter Ordentlich, Ph.D.
Chief Scientific Officer and Founder
Steve Sabus
Chief Commercial Officer
As our leading core value states, we’re both fueled and united by our enduring passion for patients. This passion not only empowers us to work to set the new standard for developing medicines, but it also forms the basis for our dedication to realize a future in which people with cancer live longer and better than ever before. In support of this dedication, we work with patient advocacy groups to understand patient journeys and align our development efforts to their needs.
